S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal with debt
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal with debt
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal with debt
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal with debt
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt

CASI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CASI)

$5.59
0.00 (0.00%)
(As of 12/1/2023 ET)
Compare
Today's Range
$5.38
$5.68
50-Day Range
$2.00
$5.85
52-Week Range
$1.45
$5.94
Volume
22,379 shs
Average Volume
N/A
Market Capitalization
$74.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

CASI Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
114.7% Upside
$12.00 Price Target
Short Interest
Healthy
2.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.50
Upright™ Environmental Score
News Sentiment
0.96mentions of CASI Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

246th out of 957 stocks

Biological Products, Except Diagnostic Industry

34th out of 159 stocks


CASI stock logo

About CASI Pharmaceuticals Stock (NASDAQ:CASI)

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

CASI Stock Price History

CASI Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
CASI Pharmaceuticals Posts Narrower Loss In Q3
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
CASI Pharmaceuticals, Inc. Q2 Loss Widens
CASI - CASI Pharmaceuticals, Inc.
See More Headlines
Receive CASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2023
Today
12/03/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/24/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CASI
Employees
224
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+114.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-41,010,000.00
Pretax Margin
-87.15%

Debt

Sales & Book Value

Annual Sales
$43.11 million
Book Value
$2.16 per share

Miscellaneous

Free Float
10,492,000
Market Cap
$74.46 million
Optionable
Not Optionable
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Wei-Wu He Ph.D. (Age 58)
    Chairman & CEO
    Comp: $565.36k
  • Dr. Wei Zhang Ph.D. (Age 63)
    President
    Comp: $1.13M
  • Dr. Alexander A. Zukiwski M.D. (Age 66)
    Executive VP & Chief Medical Officer
    Comp: $514.79k
  • Ms. Kun Qian (Age 41)
    VP & Global Controller
  • Ms. Chunhua Wang (Age 51)
    Chief Operating Officer
  • Ms. Wei Gao (Age 42)
    General Counsel
  • Dr. James E. Goldschmidt Ph.D.
    Chief Business Development Officer
  • Mr. Fuqiang Zhang (Age 54)
    Chief Commercial Officer
  • Ms. Amanda Cui
    VP & Global Controller














CASI Stock Analysis - Frequently Asked Questions

Should I buy or sell CASI Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CASI shares.
View CASI analyst ratings
or view top-rated stocks.

What is CASI Pharmaceuticals' stock price target for 2024?

1 Wall Street analysts have issued 12-month price targets for CASI Pharmaceuticals' shares. Their CASI share price targets range from $12.00 to $12.00. On average, they anticipate the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 114.7% from the stock's current price.
View analysts price targets for CASI
or view top-rated stocks among Wall Street analysts.

How have CASI shares performed in 2023?

CASI Pharmaceuticals' stock was trading at $1.79 at the start of the year. Since then, CASI stock has increased by 212.3% and is now trading at $5.59.
View the best growth stocks for 2023 here
.

Are investors shorting CASI Pharmaceuticals?

CASI Pharmaceuticals saw a decline in short interest in November. As of November 15th, there was short interest totaling 151,200 shares, a decline of 33.0% from the October 31st total of 225,700 shares. Based on an average daily volume of 30,600 shares, the short-interest ratio is currently 4.9 days. Approximately 2.5% of the company's shares are short sold.
View CASI Pharmaceuticals' Short Interest
.

When is CASI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our CASI earnings forecast
.

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its earnings results on Friday, August, 11th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.27. The biotechnology company earned $9.82 million during the quarter, compared to analyst estimates of $10.09 million. CASI Pharmaceuticals had a negative trailing twelve-month return on equity of 110.90% and a negative net margin of 95.24%.

When did CASI Pharmaceuticals' stock split?

Shares of CASI Pharmaceuticals reverse split before market open on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of CASI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Platforms (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James Huang, Weihao Xu and Wei-Wu He.
View institutional ownership trends
.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CASI) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -